| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H8ClN4O2S.Na |
| Molecular Weight | 306.704 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C2=NN=C(Cl)C=C2
InChI
InChIKey=ODWMXYHUKDMPTR-UHFFFAOYSA-N
InChI=1S/C10H8ClN4O2S.Na/c11-9-5-6-10(14-13-9)15-18(16,17)8-3-1-7(12)2-4-8;/h1-6H,12H2;/q-1;+1
Sulfachlorpyridazine is a broad spectrum antibacterial compound which is effective
in the treatment of infections caused by gram-positive and gram-negative
organisms that are commonly susceptible to sulfonamide therapy and which has
been proven by laboratory and field experiments to be highly effective against
diseases caused by Escherichia coli. Sulfachlorpyridazine has a rapid onset of action in several species of animals
following both oral and parenteral administration. Sulfachlorpyridazine (brand name Vetisulid) is especially indicated for the treatment of diarrhea caused or
complicated by E. coli (colibacillosis) in calves under 1 month of age: Vetisulid
powder is also indicated for the treatment of colibacillosis in swine. Sulfachlorpyridazine is a dihydropteroate synthase inhibitor.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Calves: The recommended daily dose is 30 to 45 mg of sulfachlorpyridazine per lb
of body weight administered in 2 divided doses for 1 to 5 days, as follows:
Vetisulid Injection (Sodium Sulfachlorpyridazine Injection) – Administer
intravenously 1 mL per 10 lb of body weight morning and night.
It is suggested that therapy be initiated by administering Vetisulid Injection intravenously and continuing therapy with oral administration of either Vetisulid
Boluses or Vetisulid Powder.
Route of Administration:
Intravenous
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
